STEPHANIE KOCHUPARAMBIL: Open Payments
NPI 1093330722 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,317 in 118 payments from 19 companies in 2025. Trend: 2023 $1,336 · 2024 $1,426 · 2025 $2,317
Food & beverage: $2,317
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $455 |
| Otsuka America Pharmaceutical, Inc. | 10 | $190 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $190 |
| Janssen Pharmaceuticals, Inc | 13 | $179 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $168 |
| ABBVIE INC. | 7 | $162 |
| E.R. Squibb & Sons, L.L.C. | 9 | $153 |
| Axsome Therapeutics, Inc. | 6 | $143 |
| Lundbeck LLC | 9 | $138 |
| Corium, LLC | 5 | $131 |
Products named: INGREZZA, REXULTI, CAPLYTA, SPRAVATO, TRINTELLIX, VRAYLAR, COBENFY, Azstarys.
Industry payments across TX — which companies pay providers there.
